Cargando…

The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures

Non-small cell lung cancer (NSCLC) represents the perfect paradigm of ‘precision medicine’ due to its complex intratumoral heterogeneity. It is truly characterized by a range of molecular alterations that can deeply influence the natural history of this disease. Several molecular alterations have be...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferrara, Miriam Grazia, Stefani, Alessio, Pilotto, Sara, Carbone, Carmine, Vita, Emanuele, Di Salvatore, Mariantonietta, D’Argento, Ettore, Sparagna, Ileana, Monaca, Federico, Valente, Giustina, Vitale, Antonio, Piro, Geny, Belluomini, Lorenzo, Milella, Michele, Tortora, Giampaolo, Bria, Emilio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733471/ https://www.ncbi.nlm.nih.gov/pubmed/35004317 http://dx.doi.org/10.3389/fonc.2021.792385

Ejemplares similares

Unweaving the mitotic spindle: A focus on Aurora kinase inhibitors in lung cancer
por: Stefani, Alessio, et al.
Publicado: (2022)

Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer
por: Carbone, Carmine, et al.
Publicado: (2019)

Leptin-mediated meta-inflammation may provide survival benefit in patients receiving maintenance immunotherapy for extensive-stage small cell lung cancer (ES-SCLC)
por: Vita, Emanuele, et al.
Publicado: (2023)

Long-term survivors with immunotherapy in advanced NSCLC: is ‘cure’ within reach?
por: Monteverdi, Sara, et al.
Publicado: (2020)

Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story
por: Piro, Geny, et al.
Publicado: (2019)

KRAS-Dependency in Pancreatic Ductal Adenocarcinoma: Mechanisms of Escaping in Resistance to KRAS Inhibitors and Perspectives of Therapy
por: Gurreri, Enrico, et al.
Publicado: (2023)

Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives
por: Ferrara, Miriam Grazia, et al.
Publicado: (2020)

PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around
por: Gkountakos, Anastasios, et al.
Publicado: (2019)

Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary Approaches
por: Cencioni, Chiara, et al.
Publicado: (2022)

Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities
por: Ferrara, Miriam Grazia, et al.
Publicado: (2021)

Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study
por: Di Noia, Vincenzo, et al.
Publicado: (2020)

Mechanisms of resistance to chemotherapeutic and anti-angiogenic drugs as novel targets for pancreatic cancer therapy
por: Tamburrino, Anna, et al.
Publicado: (2013)

Immunogenic Cell Death: An Emerging Target in Gastrointestinal Cancers
por: Chiaravalli, Marta, et al.
Publicado: (2022)

Toll-Like Receptor 9 Agonists for Cancer Therapy
por: Melisi, Davide, et al.
Publicado: (2014)

Oncological Frontiers in the Treatment of Malignant Pleural Mesothelioma
por: Vita, Emanuele, et al.
Publicado: (2021)

Angiopoietin-Like Proteins in Angiogenesis, Inflammation and Cancer
por: Carbone, Carmine, et al.
Publicado: (2018)

Pancreatic Cancer and Obesity: Molecular Mechanisms of Cell Transformation and Chemoresistance
por: Cascetta, Priscilla, et al.
Publicado: (2018)

Intraductal Pancreatic Mucinous Neoplasms: A Tumor-Biology Based Approach for Risk Stratification
por: Nasca, Vincenzo, et al.
Publicado: (2020)

Intratumoral injection of TLR9 agonist promotes an immunopermissive microenvironment transition and causes cooperative antitumor activity in combination with anti-PD1 in pancreatic cancer
por: Carbone, Carmine, et al.
Publicado: (2021)

Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research
por: Bonomi, Maria, et al.
Publicado: (2011)

Pancreatic Cancer Patient-Derived Organoid Platforms: A Clinical Tool to Study Cell- and Non-Cell-Autonomous Mechanisms of Treatment Response
por: Piro, Geny, et al.
Publicado: (2021)

KRAS RENAISSANCE(S) in Tumor Infiltrating B Cells in Pancreatic Cancer
por: Meng, Qingda, et al.
Publicado: (2018)

An angiopoietin-like protein 2 autocrine signaling promotes EMT during pancreatic ductal carcinogenesis
por: Carbone, Carmine, et al.
Publicado: (2014)

A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be done
por: Belluomini, Lorenzo, et al.
Publicado: (2021)

Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance
por: Gkountakos, Anastasios, et al.
Publicado: (2022)

Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease
por: Filippini, Dea, et al.
Publicado: (2019)

Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories
por: Sposito, Marco, et al.
Publicado: (2023)

Molecular alterations in basal cell carcinoma subtypes
por: Di Nardo, Lucia, et al.
Publicado: (2021)

Systemic profile of immune factors in an elderly Italian population affected by chronic strongyloidiasis
por: Tiberti, Natalia, et al.
Publicado: (2020)

Collagenous colitis and atezolizumab therapy: an atypical case
por: Gallo, Antonella, et al.
Publicado: (2020)

Unlocking New Horizons in Small-Cell Lung Cancer Treatment: The Onset of Antibody–Drug Conjugates
por: Belluomini, Lorenzo, et al.
Publicado: (2023)

Clinical Stage III NSCLC Patients Treated with Neoadjuvant Therapy and Surgery: The Prognostic Role of Nodal Characteristics †
por: Chiappetta, Marco, et al.
Publicado: (2022)

Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients
por: Adamo, Annalisa, et al.
Publicado: (2023)

A circulating T(H)2 cytokines profile predicts survival in patients with resectable pancreatic adenocarcinoma
por: Piro, Geny, et al.
Publicado: (2017)

Anticipating EGFR Targeting in Early Stages of Lung Cancer: Leave No Stone Unturned
por: Belluomini, Lorenzo, et al.
Publicado: (2021)

Renaissance
por: Scott, Stephen
Publicado: (1995)

The renaissance /
por: Pater, Walter, 1839-1894

Leadership in the digital era: renaissance of the renaissance person
por: Hageback, Niklas
Publicado: (2020)

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
por: Carbognin, Luisa, et al.
Publicado: (2015)

The renaissance : six essays

Cannot write session to /tmp/vufind_sessions/sess_c7r54c55p9h5722q7s6jnp3c0b